ERCC1 and progeroid syndrome: Genetic approaches have also been used to correct XP human cells (Dupuy and Sarasin, 2015), whereas genetic depletion of one allele of the p65 subunit of NF-κB or treatment with IKK inhibitors delays the age-related symptoms and pathologies of XFEPS (XPF-ERCC1 progeroid syndrome) mice, which harbour mutations in ERCC1 (involved in DNA excision repair) (Tilstra et al., 2012).